778
We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.
 a patient with acromegaly: Subject; hepatitis: Effect; long-acting somatostatin-analog octreotide: Treatment; GH receptor antagonist pegvisomant: Treatment; acromegaly: Treatment.Disorder; pegvisomant: Treatment.Drug; octreotide: Treatment.Drug; pegvisomant: Combination.Drug; octreotide: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 a patient with acromegaly: Subject; hepatitis: Effect; long-acting somatostatin-analog octreotide: Treatment; GH receptor antagonist pegvisomant: Treatment; acromegaly: Treatment.Disorder; pegvisomant: Treatment.Drug; octreotide: Treatment.Drug; pegvisomant: Combination.Drug; octreotide: Combination.Drug